Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5174869 | 0.99 | LTA4H (0.46) | LTA4HITGB3ITGA2BCYSLTR2CYSLTR1 | |
| SCHEMBL16940459 | 0.88 | ITGB3 (0.51) | LTA4HITGB3ITGA2B | |
| Acetic Acid SCHEMBL6866559 | 0.87 | ITGB3 (0.47) | LTA4HITGB3ITGA2B | |
| SCHEMBL6871466 | 0.87 | ITGB3 (0.51) | LTA4HITGB3ITGA2B | |
| SCHEMBL1541948 | 0.86 | ITGB3 (0.59) | LTA4HITGB3ITGA2BPTPN1 | |
| SCHEMBL4832539 | 0.85 | ITGB3 (0.62) | LTA4HITGB3ITGA2BCYSLTR2CYSLTR1 | |
| SCHEMBL14281122 | 0.83 | LTA4H (0.52) | LTA4HCYSLTR2CYSLTR1BRD4 | |
| SCHEMBL7358634 | 0.82 | ACACB (0.50) | LTA4HITGB3ITGA2BPTPN1 | |
| SCHEMBL7350603 | 0.81 | LTA4H (0.50) | LTA4HMAPT | |
| SCHEMBL16355748 | 0.80 | PTPN1 (0.48) | LTA4HITGB3ITGA2BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838453-B2 | Antagonist derivatives of the vitronectin receptor | AVENTIS PHARMA S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
| EP-1155003-B1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-6340679-B1 | FOR INHIBITING BONE RESORPTION, OSTEOPOROSIS, TUMOR GROWTH OR TUMOR METASTASIS, INFLAMMATION, OR FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS, RESTENOSIS, ARTERIOSCLEROSIS, NEPHROPATHIES, RETINOPATHIES OR RHEUMATOID ARTHRITIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-22 | — | — | US | disclosed |
| EP-1155003-A1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2001-11-21 | — | — | EP | disclosed |
| CN-1064352-C | Novel cyloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 2001-04-11 | — | — | CN | disclosed |
| WO-2000047564-A1 | NOVEL GUANIDINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-08-17 | — | — | WO | disclosed |
| EP-1028114-A1 | Novel guanidine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2000-08-16 | — | — | EP | disclosed |
| CN-1179418-A | Novel cyloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 1998-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | ADGRF1, BDKRB1, ADGRE5 | LTA4H 1119/4885ITGB3 220/4885ITGA2B 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.